GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LivaNova PLC (NAS:LIVN) » Definitions » EV-to-Revenue

LivaNova (LivaNova) EV-to-Revenue : 2.90 (As of Apr. 26, 2024)


View and export this data going back to 1993. Start your Free Trial

What is LivaNova EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, LivaNova's enterprise value is $3,347 Mil. LivaNova's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $1,154 Mil. Therefore, LivaNova's EV-to-Revenue for today is 2.90.

The historical rank and industry rank for LivaNova's EV-to-Revenue or its related term are showing as below:

LIVN' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.94   Med: 4.09   Max: 6.68
Current: 2.9

During the past 13 years, the highest EV-to-Revenue of LivaNova was 6.68. The lowest was 1.94. And the median was 4.09.

LIVN's EV-to-Revenue is ranked better than
51.46% of 824 companies
in the Medical Devices & Instruments industry
Industry Median: 3.04 vs LIVN: 2.90

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-26), LivaNova's stock price is $55.53. LivaNova's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $21.32. Therefore, LivaNova's PS Ratio for today is 2.60.


LivaNova EV-to-Revenue Historical Data

The historical data trend for LivaNova's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LivaNova EV-to-Revenue Chart

LivaNova Annual Data
Trend Apr14 Apr15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.68 3.94 4.57 3.27 2.74

LivaNova Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.27 2.59 2.92 2.89 2.74

Competitive Comparison of LivaNova's EV-to-Revenue

For the Medical Devices subindustry, LivaNova's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LivaNova's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, LivaNova's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where LivaNova's EV-to-Revenue falls into.



LivaNova EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

LivaNova's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=3346.884/1153.545
=2.90

LivaNova's current Enterprise Value is $3,347 Mil.
LivaNova's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,154 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LivaNova  (NAS:LIVN) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

LivaNova's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=55.53/21.319
=2.60

LivaNova's share price for today is $55.53.
LivaNova's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $21.32.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LivaNova EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of LivaNova's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


LivaNova (LivaNova) Business Description

Traded in Other Exchanges
Address
20 Eastbourne Terrace, London, GBR, W2 6LG
U.K.-based LivaNova was born of a combination between Cyberonics in the U.S. and Sorin in Italy. The medical device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. LivaNova derives roughly half of its revenue from the U.S. market, another 21% from Europe, and the remainder from the rest of the world.
Executives
James Christopher Barry director 7475 LUSK BLVD, SAN DIEGO CA 92121
Damien Mcdonald officer: COO 5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Michael Damon Hutchinson officer: Chief Legal Officer 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Brooke Story director C/O SIGILON THERAPEUTICS, INC., 100 BINNEY STREET, SUITE 600, CAMBRIDGE MA 02142
Peter M Wilver director
Daniel Jeffrey Moore director 100 CYBERONICS BVLD, HOUSTON TX 77058
Alfred J Novak director 325 NE 6TH ST, BOCA RATON FL 33432
William A Kozy director C/O BECTON DICKERSON & CO, 1 BECTON DR, FRANKLIN LAKES NJ 07417
Marco Dolci officer: SVP Global Operations, R&D VIA BENIGNO CRESPI 17, MILAN L6 20159
Todd C Schermerhorn director C/O C.R BARD INC, 730 CENTRAL AVE, MURRAY HILL NJ 07974
Alex Shvartsburg officer: Interim CFO 20 EASTBOURNE TERRACE, LONDON X0 W26LG
Roy Khoury officer: President, International 5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Thad Allen Huston officer: Chief Financial Officer 941 BLOOMFIELD ST, HOBOKEN NJ 07030
Seng Stacy Enxing director C/O HILL-ROM HOLDINGS, INC., SUITE 4100 180 NORTH STETSON AVENUE, CHICAGO IL 60601
Trui Hebbelinck officer: Chief Human Resources Officer 20 EASTBOURNE TERRACE, LONDON X0 W2 6LG